Amorphous reduced β-nicotinamide mononucleotide calcium salt and its preparation method and use

Abstract

The present invention relates to a compound, NMNH calcium salt, and more particularly to an amorphous reduced β-nicotinamide mononucleotide calcium salt, its preparation method, its use as pharmaceutical and cosmetic ingredients, and preparations containing these salts, belonging to the fields of medicine and cosmetics. Specifically, the present invention describes an amorphous NMNH calcium salt compound that exhibits long-term stability, significantly superior antioxidant properties, stability, and hygroscopic resistance to the disodium NMNH salt, and is more suitable for long-term storage and market promotion. The amorphous NMNH calcium salt compound has a simple preparation process, is easily controlled, and is suitable for large-scale production.

Description

Technical Field

[0001] The present invention relates to the field of chemical raw materials for medicine and cosmetics, and in particular to an amorphous reduced β-nicotinamide mononucleotide calcium salt, a preparation method and uses thereof. Background Art

[0002] As one of the most popular molecules in the anti-aging field, nicotinamide adenine dinucleotide (NAD + ) has become the core of anti-aging substances throughout the ages. + It is an important coenzyme required for more than 500 enzymatic reactions and is well known for its role in oxidation and reduction (Ansari and Raghava, 2010; Rajman et al., 2018; Stein and Imai, 2012). More and more studies indicate that increasing NAD + Equivalent doses can significantly improve multiple organ functions, including liver function, kidney function, heart function, and skeletal muscle function (Canto et al., 2012; Mills et al., 2016; Rajman et al., 2018). + It can be synthesized using tryptophan in the de novo biosynthesis pathway, nicotinic acid (NA) in the preiss-handler pathway, and nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN) in the salvage pathway (Canto et al., 2015; Chiarugi et al., 2012; Johnson and Imai, 2018). In particular, as NAD + The key intermediates, NAM, NR, and NMN, have been extensively studied for their potential therapeutic effects in many mouse disease models (Mills et al., 2016), among which NMN is currently considered the most suitable NAD + Precursor, and currently NMN is hot-selling in the global market and is highly favored by consumers.

[0003] NMNH (molecular structure as shown in formula (A)) is called "reduced nicotinamide mononucleotide" or "reduced β-nicotinamide mononucleotide" in Chinese. It is the reduced form of NMN and is a supplement to NAD. + A new precursor of NAD with better NMN properties + The promoting effect and other biological functions such as increasing cellular antioxidant capacity, reducing fat accumulation, reducing inflammatory response and inhibiting tumor cell growth are considered to be health-promoting agents with significant commercial potential (WO2021098725A1).

[0004]

[0005] NMNH is the reduced form of NMN. It is sensitive to air, easily oxidized, and unstable, making it unfavorable for long-term storage and market promotion. WO2023160405 (A1) reports on NMNH disodium salt compounds and their crystal forms and amorphous forms. When placed open in a stability test chamber at 25°C and 65% RH, the amorphous powder of NMNH disodium salt turned into oil after 1 day and the purity dropped from 99.30% to 99.02%. The purity of NMNH disodium salt crystal form A solid dropped from 99.33% to 99.01% after 5 days. Such stability cannot meet the shelf life of the product and is not conducive to the market promotion of the product.

[0006] Therefore, there is still an urgent need in this field to develop new salt forms of NMNH compounds with better stability, better suitability for long-term storage and market promotion. Summary of the Invention

[0007] The present invention aims to provide a new salt form of NMNH compounds with better stability and better long-term storage, and specifically relates to an amorphous form of reduced β-nicotinamide mononucleotide calcium salt, as well as its preparation method and use.

[0008] In the first aspect of the present invention, there is provided an amorphous compound of a reduced β-nicotinamide mononucleotide calcium salt as shown in formula (I),

[0009]

[0010] The amorphous form is selected from the group consisting of amorphous form A, amorphous form B, amorphous form C, and amorphous form D.

[0011] In another preferred embodiment, the XRPD spectrum of the amorphous form A is substantially as follows Figure 1 Represented.

[0012] In another preferred embodiment, the amorphous A 1 The H NMR spectrum is basically as Figure 5 Represented.

[0013] In another preferred embodiment, the XRPD spectrum of the amorphous form B is substantially as follows Figure 2 Represented.

[0014] In another preferred embodiment, the amorphous B 1 The H NMR spectrum is basically as Figure 5 Represented.

[0015] In another preferred embodiment, the XRPD spectrum of the amorphous C is substantially as follows Figure 3 Represented.

[0016] In another preferred embodiment, the amorphous C1 The H NMR spectrum is basically as Figure 5 Represented.

[0017] In another preferred embodiment, the XRPD spectrum of the amorphous form D is substantially as follows: Figure 4 Represented.

[0018] In another preferred embodiment, the amorphous D 1 The H NMR spectrum is basically as Figure 5 Represented.

[0019] In a second aspect of the present invention, a method for preparing the amorphous compound according to the first aspect is provided, the method comprising the following steps:

[0020] 1) adding reduced β-nicotinamide mononucleotide calcium salt to a first solvent to obtain a solution containing reduced β-nicotinamide mononucleotide calcium salt, or generating a reduced β-nicotinamide mononucleotide calcium salt solution in situ in the reaction solution;

[0021] 2) adding the solution obtained in 1) above to a second solvent to precipitate a solid to obtain an amorphous reduced β-nicotinamide mononucleotide calcium salt compound; or freeze-drying or spray-drying the solution obtained in 1) above to obtain an amorphous reduced β-nicotinamide mononucleotide calcium salt compound; or slurrying the reduced β-nicotinamide mononucleotide calcium salt solid in a second solvent to obtain the amorphous reduced β-nicotinamide mononucleotide calcium salt compound as described in the first aspect.

[0022] In another preferred embodiment, the method is prepared by any one of the following methods (I) to (IV):

[0023] (I) Preparation of Amorphous Form A

[0024] I-1) providing a solution of reduced β-nicotinamide mononucleotide calcium salt in a first solvent;

[0025] I-2) adding the solution obtained in I-1) above to a second solvent, and drying the precipitated solid at 30-45° C. to obtain amorphous form A;

[0026] Wherein, the first solvent is selected from: water; the second solvent is selected from: methanol, or a mixed solvent of methanol and water;

[0027] (II) Preparation of Amorphous Form B

[0028] II-1) providing a solution of reduced β-nicotinamide mononucleotide calcium salt in a first solvent;

[0029] II-2) adding the solution obtained in II-1) above to a second solvent, and drying the precipitated solid at 30-45° C. to obtain amorphous form B;

[0030] Wherein, the first solvent is selected from: water; the second solvent is selected from: ethanol, or a mixed solvent of ethanol and water;

[0031] (III) Preparation of Amorphous C

[0032] III-1) providing a solution of reduced β-nicotinamide mononucleotide calcium salt in a first solvent;

[0033] III-2) adding the solution obtained in III-1) above to a second solvent, and drying the precipitated solid at 30-45° C. to obtain amorphous form C;

[0034] Wherein, the first solvent is selected from: water; the second solvent is selected from: acetone, or a mixed solvent of acetone and water;

[0035] (IV) Preparation of Amorphous Form D

[0036] IV-1) providing a solution of reduced β-nicotinamide mononucleotide calcium salt in a first solvent;

[0037] IV-2) drying the solution obtained in IV-1) to obtain amorphous form D;

[0038] The drying process includes freeze drying, spray drying, reduced pressure vacuum drying, rotary evaporation drying, etc.

[0039] In another preferred embodiment, the first solvent and the second solvent are the same or different, and are independently selected from the following group: water, acetonitrile, tetrahydrofuran, methyl tert-butyl ether, 2-methyltetrahydrofuran, dichloromethane, N,N-dimethylformamide, N,N-dimethylacetamide, N,N-diethylformamide, dimethyl sulfoxide, ethyl acetate, isopropyl acetate, ketone solvents, alcohol solvents, or a combination thereof.

[0040] In another preferred embodiment, the ketone solvent is selected from the following group: acetone, 2-butanone, methyl isobutyl ketone, methyl tert-butyl ketone, 3-methyl-2-butanone, or a combination thereof.

[0041] In another preferred embodiment, the alcohol solvent is selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, n-pentanol, or a combination thereof.

[0042] In another preferred embodiment, the solution of reduced β-nicotinamide mononucleotide calcium salt in the first solvent is provided by the following method: adding reduced β-nicotinamide mononucleotide calcium salt to the first solvent to obtain a solution containing reduced β-nicotinamide mononucleotide calcium salt, or generating the reduced β-nicotinamide mononucleotide calcium salt solution in situ in the reaction solution.

[0043] In the third aspect of the present invention, a composition is provided, comprising: (a) the amorphous compound as described in the first aspect, and (b) a pharmaceutically acceptable excipient or carrier, or a cosmetically acceptable excipient or carrier.

[0044] In another preferred embodiment, the composition is selected from the following group: a pharmaceutical composition and a cosmetic composition.

[0045] In another preferred embodiment, the pharmaceutical composition comprises: (a) the amorphous compound described in the first aspect, and (b) a pharmaceutically acceptable excipient or carrier.

[0046] In another preferred embodiment, the dosage form of the pharmaceutical composition is selected from the following groups: oral preparations, injection dosage forms, respiratory tract administration dosage forms, skin administration dosage forms, mucosal administration dosage forms, cavity administration dosage forms, etc.

[0047] In another preferred embodiment, the cosmetic composition comprises: (a) the amorphous compound described in the first aspect, and (b) a cosmetically acceptable excipient or carrier.

[0048] In another preferred embodiment, the cosmetic composition includes cosmetics selected from the following groups: skin cosmetics, hair cosmetics, beauty cosmetics, and special function cosmetics.

[0049] In a fourth aspect of the present invention, there is provided a use of the amorphous compound described in the first aspect for preparing medicines or cosmetics.

[0050] In another preferred embodiment, the drug is used to protect the optic nerve, improve retinal damage, prevent / treat hair loss, prevent / improve cardiovascular and cerebrovascular diseases, inhibit renal tubular damage and aging, prevent liver fibrosis, improve fatty liver disease, improve dry eye symptoms, repair kidney damage, prevent diabetes / nephropathy, improve sarcopenia symptoms in the elderly, treat chronic inflammation, alleviate the condition of patients with polycystic ovary syndrome, prevent / delay glaucoma, reduce neuroinflammation, reduce the cardiac toxicity of anthracycline chemotherapy drugs, assist in cerebral infarction recovery, prevent and treat heart failure in the elderly, etc.

[0051] In another preferred embodiment, the cosmetic is used to improve the function of damaged cells, improve skin quality / hair quality, prevent / treat skin photoaging, maintain skin softness and elasticity, delay skin aging, etc.

[0052] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1The XRPD pattern of NMNH calcium salt amorphous form A is shown.

[0054] Figure 2 The XRPD pattern of NMNH calcium salt amorphous form B is shown.

[0055] Figure 3 The XRPD pattern of NMNH calcium salt amorphous form C is shown.

[0056] Figure 4 The XRPD pattern of NMNH calcium salt amorphous form D is shown.

[0057] Figure 5 The amorphous NMNH calcium salt is shown 1 H NMR spectrum. DETAILED DESCRIPTION

[0058] Through extensive and in-depth research, the inventors unexpectedly developed a specific salt of NMNH, the calcium salt of NMNH, for the first time. Their research demonstrated that the amorphous form of the calcium salt of NMNH exhibits excellent stability. Compared to the crystalline and amorphous forms of the disodium salt of NMNH, the amorphous form of the calcium salt of NMNH exhibits long-term stability and hygroscopic resistance, making it more suitable for long-term storage and market promotion. Furthermore, the amorphous compound of the present invention meets the shelf life of commercial products and is suitable for use in pharmaceutical compositions, cosmetics, and the like. Based on this, the inventors completed the present invention.

[0059] Terminology

[0060] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0061] NMNH calcium salt

[0062] As used herein, the terms "reduced β-nicotinamide mononucleotide calcium salt," "β-dihydronicotinamide mononucleotide calcium salt," "dihydronicotinamide mononucleotide calcium salt," "reduced nicotinamide mononucleotide calcium salt," "reduced NMN calcium salt," "NMNH calcium salt," and "NMNH-Ca" are used interchangeably and refer to the salt of reduced β-nicotinamide mononucleotide and calcium ions, the structure of which is shown in Formula (I). It should be understood that the term includes amorphous forms, hydrates, solvates, solvates-hydrates, and anhydrates.

[0063]

[0064] Use of the reduced β-nicotinamide mononucleotide calcium salt of the present invention

[0065] The present invention provides the use of an amorphous NMNH calcium salt compound. The compound has high efficiency and broad spectrum, and can be used in pharmaceutical compositions, cosmetics, and the like.

[0066] Compared with the prior art, the present invention has the following beneficial effects:

[0067] (1) The amorphous solid of the compound of formula (I) of the present invention has better antioxidant properties and stability, lower hygroscopicity, and is more conducive to subsequent formulation process operation, long-term storage and market promotion than the NMNH disodium salt crystalline form and amorphous solid.

[0068] (2) The preparation method of the amorphous solid compound of formula (I) of the present invention is simple and suitable for industrial production.

[0069] (3) The amorphous solid compound of formula (I) of the present invention can be used in pharmaceutical compositions, cosmetics, etc.

[0070] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.

[0071] Unless otherwise defined, all professional and scientific terms used herein have the same meaning as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention.

[0072] Unless otherwise specified, the experimental materials and reagents used in the following examples can be obtained from commercial channels.

[0073] Test method:

[0074] XRPD (X-ray powder diffraction) pattern determination method: Bruker D2 Phaser X-ray powder diffractometer; radiation source Cu

[0075] The measurement differences associated with such X-ray powder diffraction analysis results are caused by a variety of factors including: (a) errors in sample preparation (e.g., sample height), (b) instrument errors, (c) calibration differences, (d) operator errors (including errors occurring when determining peak positions), and (e) the nature of the material (e.g., preferred orientation errors). Calibration errors and sample height errors often result in displacements of all peaks in the same direction. When a flat support is used, small differences in sample height will result in large displacements of XRPD peak positions. Systematic studies have shown that a sample height difference of 1 mm can result in peak displacements of up to 1° of 2θ. These displacements can be identified from the XRPD pattern and can be eliminated by compensating for the displacement (applying the system calibration factor to all peak position values) or recalibrating the instrument. As described above, by applying the system calibration factor to make the peak positions consistent, measurement errors from different instruments can be corrected.

[0076] Example 1. Preparation of NMNH calcium salt aqueous solution

[0077] Add 1.7 kg of β-NMN and 0.94 kg of sodium dithionite to 10 liters of saturated sodium bicarbonate aqueous solution, stir at room temperature overnight, filter to obtain a clear solution, and adjust the pH of the solution to 3-4 with 37% hydrochloric acid. Desalt the solution by electrodialysis until the conductivity drops to 50-100 μS. Adjust the pH of the solution to 10 with calcium hydroxide; alternatively, add 0.57 kg of calcium chloride and adjust the pH of the solution to 10 with sodium hydroxide. This yields an aqueous solution of NMNH calcium salt containing approximately 1.71 kg of NMNH calcium salt (94.5% purity as determined by HPLC).

[0078] Example 2. Preparation of NMNH calcium salt amorphous solid A

[0079] 500 ml of NMNH calcium salt aqueous solution was added dropwise to 2 L of stirred methanol. After the addition was complete, the mixture was stirred for 1 h, filtered, and dried at 30-45 °C to obtain 80.3 g of NMNH calcium salt amorphous form A product with a yield of 85.0% and a purity of 99.5%.

[0080] The obtained solid was subjected to X-ray powder diffraction test, and the XRPD pattern of the obtained NMNH calcium salt amorphous form A was basically as follows Figure 1 As shown, 1 The H NMR spectrum is basically as Figure 5 shown.

[0081] Example 3. Preparation of NMNH calcium salt amorphous solid B

[0082] 500 ml of NMNH calcium salt aqueous solution was added dropwise to 2 L of stirred ethanol. After the addition was complete, the mixture was stirred for 1 h, filtered, and dried at 30-45°C to obtain 82.6 g of NMNH calcium salt amorphous form B product with a yield of 87.5% and a purity of 99.2%.

[0083] The obtained solid was subjected to X-ray powder diffraction test, and the XRPD pattern of the obtained NMNH calcium salt amorphous form B was basically as follows Figure 2 As shown, 1 The H NMR spectrum is basically as Figure 5 shown.

[0084] Example 4. Preparation of NMNH calcium salt amorphous C solid

[0085] 500 ml of NMNH calcium salt aqueous solution was added dropwise to 2 L of stirred acetone. After the addition was complete, the mixture was stirred for 1 h, filtered, and dried at 30-45°C to obtain 83.5 g of NMNH calcium salt amorphous form C product with a yield of 88.4% and a purity of 99.1%.

[0086] The obtained solid was subjected to X-ray powder diffraction test, and the XRPD pattern of the obtained NMNH calcium salt amorphous C was basically as follows Figure 3 As shown, 1 The H NMR spectrum is basically as Figure 5 shown.

[0087] Example 5. Preparation of NMNH calcium salt amorphous D solid

[0088] 10.0 g of NMNH calcium salt amorphous form A solid was dissolved in 100 ml of purified water and freeze-dried to obtain 9.8 g of NMNH calcium salt amorphous form D product with a yield of 98% and a purity of 99.5%.

[0089] The obtained solid was subjected to X-ray powder diffraction test, and the XRPD pattern of the obtained NMNH calcium salt amorphous form D was basically as follows Figure 4 As shown, 1 The H NMR spectrum is basically as Figure 5 shown.

[0090] Example 6. Preparation of NMNH calcium salt amorphous solid D

[0091] 10.0 g of NMNH calcium salt amorphous form A solid was dissolved in 100 ml of purified water and spray-dried to obtain 9.0 g of NMNH calcium salt amorphous form D product with a yield of 90% and a purity of 99.5%.

[0092] The obtained solid was subjected to X-ray powder diffraction test, and the XRPD pattern of the obtained NMNH calcium salt amorphous form D was basically as follows Figure 4 As shown, 1 The H NMR spectrum is basically as Figure 5 shown.

[0093] Example 7. Stability of NMNH calcium salt amorphous solids A / B / C / D and NMNH disodium salt crystal form A and amorphous solids contrast

[0094] The NMNH calcium salt amorphous solids A / B / C / D were respectively placed in an open stability test chamber at 25°C and 65% RH to investigate the stability, and the data shown in Tables 1 and 2 were obtained.

[0095] Table 1 Comparison of the stability of NMNH calcium salt amorphous solid and NMNH disodium salt crystal form A and amorphous solid (25°C, 65% RH)

[0096]

[0097] Table 2 Study on Hygroscopicity of Amorphous Solid NMNH Calcium Salt (25°C, 65% RH)

[0098]

[0099] According to WO2023160405 (A1), when NMNH disodium salt is stored in the air, both crystal forms B and C absorb water and transform into crystal form A. After saturation with water, the moisture content of crystal form A is 19%-30% (high water content), and the purity drops from 99.33% to 99.01% after 5 days. The amorphous solid of NMNH disodium salt is more unstable in the air. After being placed for 1 day, it absorbs water from powder to oil, and the purity drops from 99.30% to 99.02%.

[0100] As can be seen from Tables 1 and 2, the amorphous solid of NMNH calcium salt remains a solid powder after 60 days of storage, with almost no change in purity and moisture. In other words, the amorphous solid of NMNH calcium salt can be left open at 25°C and 65% RH for at least 60 days with sustained purity and moisture stability. However, both the crystalline form A and the amorphous form of NMNH disodium salt are unstable and easily absorb water, making them extremely difficult to store, unable to meet the shelf life of the product, and difficult to market and promote. This shows that the stability and hygroscopic resistance of the amorphous solid of NMNH calcium salt have been significantly improved, which is beneficial for subsequent formulation process operations and long-term stable storage, making it easier to market and promote.

[0101] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. An amorphous compound of reduced β-nicotinamide mononucleotide calcium salt as represented by formula (I), It is characterized by: The amorphous type is selected from the group consisting of amorphous type A, amorphous type B, amorphous type C, or amorphous type D; Wherein, the XRPD spectrum of the amorphous form A is basically represented as shown in Figure 1; The XRPD spectrum of the amorphous form B is basically as shown in Figure 2; The XRPD spectrum of the amorphous C is basically as shown in Figure 3; The XRPD spectrum of the amorphous form D is basically represented by FIG4 .

2. A method for preparing the amorphous compound according to claim 1, characterized in that: The method is prepared by any one of the following methods (I) to (IV): (I) Preparation of Amorphous Form A I-1) providing a solution of reduced β-nicotinamide mononucleotide calcium salt in a first solvent; I-2) adding the solution obtained in I-1) above to a second solvent, and drying the precipitated solid at 30-45° C. to obtain amorphous form A; Wherein, the first solvent is selected from: water; the second solvent is selected from: methanol, or a mixed solvent of methanol and water; (II) Preparation of Amorphous Form B II-1) providing a solution of reduced β-nicotinamide mononucleotide calcium salt in a first solvent; II-2) adding the solution obtained in II-1) above to a second solvent, and drying the precipitated solid at 30-45° C. to obtain amorphous form B; Wherein, the first solvent is selected from: water; the second solvent is selected from: ethanol, or a mixed solvent of ethanol and water; (III) Preparation of Amorphous C III-1) providing a solution of reduced β-nicotinamide mononucleotide calcium salt in a first solvent; III-2) adding the solution obtained in III-1) above to a second solvent, and drying the precipitated solid at 30-45° C. to obtain amorphous form C; Wherein, the first solvent is selected from: water; the second solvent is selected from: acetone, or a mixed solvent of acetone and water; (IV) Preparation of Amorphous Form D IV-1) providing a solution of reduced β-nicotinamide mononucleotide calcium salt in a first solvent; IV-2) drying the solution obtained in IV-1) to obtain amorphous form D; Wherein, the drying treatment is: freeze drying, spray drying, reduced pressure vacuum drying, and rotary evaporation drying.

3. A composition, characterized in that The composition comprises: (a) the amorphous compound according to claim 1, and (b) a pharmaceutically acceptable excipient or a cosmetically acceptable excipient.

4. The composition according to claim 3, wherein The composition is selected from the following groups: pharmaceutical composition and cosmetic composition.

5. The composition according to claim 4, wherein The pharmaceutical composition comprises: (a) the amorphous compound according to claim 1, and (b) a pharmaceutically acceptable excipient.

6. The composition according to claim 4, wherein The dosage form of the pharmaceutical composition is selected from the following group: oral preparation, injection dosage form, respiratory tract administration dosage form, skin administration dosage form, mucosal administration dosage form, and cavity administration dosage form.

7. The composition according to claim 4, wherein The cosmetic composition comprises: (a) the amorphous compound according to claim 1, and (b) cosmetically acceptable excipients.

8. The composition according to claim 4, wherein The cosmetic composition comprises cosmetics selected from the following groups: skin cosmetics, hair cosmetics, beauty cosmetics, and special function cosmetics.

9. Use of the amorphous compound according to claim 1, characterized in that: Used in the preparation of cosmetics.

Images